1. Home
  2. MYGN vs LSAK Comparison

MYGN vs LSAK Comparison

Compare MYGN & LSAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$5.00

Market Cap

444.2M

Sector

Health Care

ML Signal

HOLD

Logo Lesaka Technologies Inc.

LSAK

Lesaka Technologies Inc.

HOLD

Current Price

$4.92

Market Cap

412.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYGN
LSAK
Founded
1991
1997
Country
United States
South Africa
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Investment Bankers/Brokers/Service
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
444.2M
412.9M
IPO Year
1996
2005

Fundamental Metrics

Financial Performance
Metric
MYGN
LSAK
Price
$5.00
$4.92
Analyst Decision
Buy
Analyst Count
7
0
Target Price
$7.64
N/A
AVG Volume (30 Days)
1.3M
87.4K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$771,400,000.00
$659,701,000.00
Revenue This Year
$6.89
$14.35
Revenue Next Year
$5.35
$8.60
P/E Ratio
N/A
N/A
Revenue Growth
2.33
16.92
52 Week Low
$3.76
$3.40
52 Week High
$8.59
$5.54

Technical Indicators

Market Signals
Indicator
MYGN
LSAK
Relative Strength Index (RSI) 56.21 50.88
Support Level $4.23 $4.80
Resistance Level $5.67 $4.98
Average True Range (ATR) 0.29 0.14
MACD 0.07 -0.02
Stochastic Oscillator 70.69 36.54

Price Performance

Historical Comparison
MYGN
LSAK

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

About LSAK Lesaka Technologies Inc.

Lesaka Technologies Inc provides payment solutions, transaction processing solutions, and financial technologies. The company operates three reportable segments: Merchant, Consumer and Enterprise. Merchant, which focuses on both formal and informal sector merchants. Consumer, which focuses on individuals who have historically been excluded from traditional financial services and to whom it offers transactional accounts (banking), insurance, lending (short-term loans), payments solutions and various value-added services; and Enterprise, which comprises large-scale corporate and government organizations, including but not limited to banks, mobile network operators (MNOs) and municipalities, and, through Recharger, landlords utilizing Recharger's prepaid electricity metering solution.

Share on Social Networks: